Navigation Links
Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
Date:12/17/2008

MUMBAI, India, Dec. 17 /PRNewswire/ -- Pharma Major, Lupin Ltd. announced today that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough's "Clarinex"(R) tablets.

As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances.

Lupin had earlier filed a Paragraph IV certification to, among others, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon - resulting in the subsequent litigation by Schering Corp. and Sepracor.

Schering-Plough's Clarinex(R) tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Commenting on the settlement, Dr. Kamal Sharma, Managing Director, Lupin said - "The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in the U.S. markets. Furthermore, the settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on Research & Development and the quality of our Intellectual property - a testimony to Lupin's larger goal of developing and delivering quality, cost-effective drugs for everybody."

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabeto
'/>"/>

SOURCE Lupin Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
2. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
3. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
4. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
5. Lupin Launches Ramipril Capsules
6. Lupin Receives USFDA Approval for Topiramate Tablets
7. Dynatronics Announces Changes to Board and Launches Operational Improvement Process
8. SantaFe Senior Living Announces Leadership Transition
9. Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM
10. Finesse Announces TruDO Optical Autoclavable Sensors for Bioprocess Applications
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... of the top public health concerns in the United ... as obese as of 2012. As health problems such ... to Twitter to discuss the problem. , A new ... at the Brown School at Washington University in St. ... tweets to track Twitter conversations about the issue of ...
(Date:7/10/2014)... EAST LANSING, Mich. For those students looking to ... answer may not be spending more time in a ... New Michigan State University research shows that students who ... on MSU,s campus during their freshman and sophomore years ... The research also indicated that students with memberships stayed ...
(Date:7/10/2014)... at the University of Huddersfield could help to improve ... food products such as butter, mayonnaise, yoghurt and ... an international profile for her work. , Katerina gained ... the University and now she has embarked on research ... Vassilis Kontogiorgos, she is investigating the potential of carbohydrates ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Want a higher GPA in college? Join a gym 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2
... panic. The following summarizes a new list of suggestions ... non-partisan National Center for Policy Analysis. Authored by NCPA ... full article is not sponsored by any commercial entity, ... Link to full article: http://www.ncpa.org/pdfs/Seven_Ways_Job_3-16-09-FINAL-A.pdf Here ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... 17 eCardio Diagnostics ( www.ecardio.com ) announced ... Medicine initiative to provide a tailored offering to ... time an arrhythmia monitoring company has addressed the ... medical centers. "At eCardio, we work closely ...
... Leading HIFU device in Mexico for Minimally Invasive ... draws attention from elite urologistsCHARLOTTE, N.C., March 16 ... the Mexican and international entities of USHIFU, a ... of high intensity focused ultrasound (HIFU) technologies, will ...
... Boston, Mass. - Many households harbor a threat to ... tables and tables with glass panels. A review by ... publisher of Consumer Reports, finds that glass-table injuries aren,t ... could have been avoided had tempered glass been used. ...
... Less Than $1 MillionGross Margin Increases to 57.1%Programs ... & 2010First Quarter Sales Off to Strong StartMONROVIA, ... STAA ), a leading developer, manufacturer ... reported financial results for the fourth quarter and ...
Cached Medicine News:Health News:7 Ways to Keep Health Coverage If You Lose Your Job 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:eCardio Diagnostics Launches Academic Medicine Initiative 2Health News:High Intensity Focused Ultrasound Physician Training Seminar in Mexico City 2Health News:Glass tables: An overlooked safety threat 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 4Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 5Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 6Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 7Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 8Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 9Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 10Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 11Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 12Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 13Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 14Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 15Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 16Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 17Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 18Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 19Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 20Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 21Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 22Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 23Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 24Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 25
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... PharmAthene, Inc. (NYSE Amex: PIP ) a ... threats, announced today that it will be hosting a ... at 4:30 p.m. E.T., to review the status of ... the United States is 866-788-0540. The dial-in number ...
... Results from two prospective, double-blind placebo controlled multi-center studies ... European efficacy and safety data in patients with focal ... at the American Academy of Neurology,s (AAN) 61st annual ... Merz Pharmaceuticals, which plans to file a Biologic License ...
Cached Medicine Technology:PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 2Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 3Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 4Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: